Mar 01, 2024 8:20am EST Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
Feb 16, 2024 4:05pm EST Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Feb 15, 2024 8:00am EST Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules